Rheumatoid arthritis: Anti-TNF and anti-IL-17 antibodies - Better together!

Nature Reviews Rheumatology

Volumn 10, Issue 12, 2014, Pages 699-

  Buckland, Jenny ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; INTERLEUKIN 17; INTERLEUKIN 17 ANTIBODY; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY; ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MEGADOSE; DRUG POTENTIATION; HUMAN; LOW DRUG DOSE; NONHUMAN; NOTE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYNOVIOCYTE; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; INTERLEUKIN-17; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84927178094     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2014.183     Document Type: Note

References (1)

1. Fischer, J. A. A. et al. Combined inhibition of TNFα and IL-17 as therapeutic opportunity for treatment in rheumatoid arthritis: development and characterization of a novel bispecific antibody. Arthritis Rheumatol. doi:10.1002/art.38896